ASX:SPLStarpharma Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Starpharma Holdings Limited Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add A$1.00 0.00 (0.00 %) (As of 05/13/2020) Add Compare Share Today's RangeA$0.98Now: A$1.00▼A$1.0150-Day RangeA$0.77MA: A$0.94▼A$1.1252-Week RangeA$0.62Now: A$1.00▼A$1.45Volume351,391 shsAverage Volume544,824 shsMarket Capitalization$372.54 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsEarningsInsider TradesHeadlines Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company focuses on the development of VivaGel, which has completed Phase III clinical trials for the management and prevention of bacterial vaginosis, and as a condom coating for the prevention of sexually transmitted infections, as well as VivaGel condom, an antiviral condom. It also develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials for the treatment of a range of tumors, such as breast, prostate, and lung; and DEP cabazitaxel that is in Phase 1/2 clinical trial for solid tumors, as well as DEP irinotecan, an anti-cancer drug used to treat colorectal cancer. The company was founded in 1996 and is headquartered in Abbotsford, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Starpharma. Previous Next 2.3 Community Rank Outperform VotesStarpharma has received 78 “outperform” votes. (Add your “outperform” vote.)Underperform VotesStarpharma has received 89 “underperform” votes. (Add your “underperform” vote.)Community SentimentStarpharma has received 53.29% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Starpharma and other stocks. Vote “Outperform” if you believe SPL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SPL will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldStarpharma does not currently pay a dividend.Dividend GrowthStarpharma does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Starpharma insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Starpharma are expected to decrease by -100.00% in the coming year, from A$0.03 to A$0.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Starpharma is -27.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Starpharma is -27.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioStarpharma has a P/B Ratio of 9.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.46 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolASX:SPL Previous Symbol CUSIPN/A CIKN/A Webwww.starpharma.com Phone+61-3-85322700Debt Debt-to-Equity Ratio4.92 Current Ratio6.05 Quick Ratio6.01Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio33.33 P/E GrowthN/A Sales & Book Value Annual Sales$7.73 million Price / Sales48.19 Cash FlowA$0.10 per share Price / Cash Flow10.42 Book ValueA$0.10 per share Price / Book9.80Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares372,542,016Market Cap$372.54 million Next Earnings DateN/A OptionableNot Optionable Receive SPL News and Ratings via Email Sign-up to receive the latest news and ratings for SPL and its competitors with MarketBeat's FREE daily newsletter. Starpharma (ASX:SPL) Frequently Asked Questions How has Starpharma's stock been impacted by COVID-19 (Coronavirus)? Starpharma's stock was trading at A$0.99 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SPL stock has increased by 1.0% and is now trading at A$1.00. View which stocks have been most impacted by Coronavirus. How were Starpharma's earnings last quarter? Starpharma Holdings Limited (ASX:SPL) posted its quarterly earnings data on Wednesday, February, 27th. The company reported ($0.02) EPS for the quarter. View Starpharma's earnings history. Has Starpharma been receiving favorable news coverage? News stories about SPL stock have been trending very negative recently, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Starpharma earned a coverage optimism score of -3.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutStarpharma. Who are some of Starpharma's key competitors? Some companies that are related to Starpharma include NGM Biopharmaceuticals (NGM), Concordia International (CXR), Clinuvel Pharmaceuticals (CUV), BELLUS Health (BLU), Trillium Therapeutics (TRIL), Aptose Biosciences (APS), PureTech Health (PRTC), Bellus Health (BLU), CEL-SCI (CVM), Oxford BioMedica (OXB), Cel-Sci (CVM), SIGA Technologies (SIGA), Paradigm Biopharmaceuticals (PAR), Biotest (BIO) and Neptune Wellness Solutions (NEPT). View all competitors. What other stocks do shareholders of Starpharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Starpharma investors own include Allena Pharmaceuticals (ALNA), Aurora Cannabis (ACBFF), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX), Ampio Pharmaceuticals (AMPE), Amira Nature Foods (ANFI), Apellis Pharmaceuticals (APLS) and Aquantia (AQ). Who are Starpharma's key executives? Starpharma's management team includes the following people: Dr. Jacinth K. Fairley B.Sc., B.V.Sc.(Hons), MBA, GAICD, CEO, MD & Exec. Director (Age 56)Mr. Nigel J. Baade, CFO & Company Sec.Dr. A. Eglezos BSc(Hons), Ph.D., MBA, VP of Bus. Devel.Dr. Jeremy R. Paull BSc (Hons), Ph.D., VP of Devel. & Regulatory AffairsDr. David J. Owen BSc(Hons) Ph.D., VP of Research What is Starpharma's stock symbol? Starpharma trades on the ASX under the ticker symbol "SPL." What is Starpharma's stock price today? One share of SPL stock can currently be purchased for approximately A$1.00. How big of a company is Starpharma? Starpharma has a market capitalization of $372.54 million and generates $7.73 million in revenue each year. What is Starpharma's official website? The official website for Starpharma is www.starpharma.com. How can I contact Starpharma? Starpharma's mailing address is 4-6 Southampton Cres, MELBOURNE, VIC 3067, Australia. The company can be reached via phone at +61-3-85322700. This page was last updated on 5/26/2020 by MarketBeat.com Staff
